Unknown

Dataset Information

0

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.


ABSTRACT: The human epidermal growth factor receptor (HER)2 provides an excellent target for selective delivery of cytotoxic drugs to tumor cells by antibody-drug conjugates (ADC) as has been clinically validated by ado-trastuzumab emtansine (Kadcyla(TM)). While selecting a suitable antibody for an ADC approach often takes specificity and efficient antibody-target complex internalization into account, the characteristics of the optimal antibody candidate remain poorly understood. We studied a large panel of human HER2 antibodies to identify the characteristics that make them most suitable for an ADC approach. As a model toxin, amenable to in vitro high-throughput screening, we employed Pseudomonas exotoxin A (ETA') fused to an anti-kappa light chain domain antibody. Cytotoxicity induced by HER2 antibodies, which were thus non-covalently linked to ETA', was assessed for high and low HER2 expressing tumor cell lines and correlated with internalization and downmodulation of HER2 antibody-target complexes. Our results demonstrate that HER2 antibodies that do not inhibit heterodimerization of HER2 with related ErbB receptors internalize more efficiently and show greater ETA'-mediated cytotoxicity than antibodies that do inhibit such heterodimerization. Moreover, stimulation with ErbB ligand significantly enhanced ADC-mediated tumor kill by antibodies that do not inhibit HER2 heterodimerization. This suggests that the formation of HER2/ErbB-heterodimers enhances ADC internalization and subsequent killing of tumor cells. Our study indicates that selecting HER2 ADCs that allow piggybacking of HER2 onto other ErbB receptors provides an attractive strategy for increasing ADC delivery and tumor cell killing capacity to both high and low HER2 expressing tumor cells.

SUBMITTER: de Goeij BE 

PROVIDER: S-EPMC3984328 | biostudies-literature | 2014 Mar-Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

de Goeij Bart E C G BE   Peipp Matthias M   de Haij Simone S   van den Brink Edward N EN   Kellner Christian C   Riedl Thilo T   de Jong Rob R   Vink Tom T   Strumane Kristin K   Bleeker Wim K WK   Parren Paul W H I PW  

mAbs 20140103 2


The human epidermal growth factor receptor (HER)2 provides an excellent target for selective delivery of cytotoxic drugs to tumor cells by antibody-drug conjugates (ADC) as has been clinically validated by ado-trastuzumab emtansine (Kadcyla(TM)). While selecting a suitable antibody for an ADC approach often takes specificity and efficient antibody-target complex internalization into account, the characteristics of the optimal antibody candidate remain poorly understood. We studied a large panel  ...[more]

Similar Datasets

2024-05-08 | GSE262579 | GEO
| S-EPMC8308903 | biostudies-literature
| S-EPMC9122332 | biostudies-literature
| S-EPMC4408264 | biostudies-literature
| S-EPMC8205919 | biostudies-literature
2024-07-18 | PXD044622 | Pride
| S-EPMC3960126 | biostudies-literature
| S-EPMC10362027 | biostudies-literature
| S-EPMC7551206 | biostudies-literature
| S-EPMC6722706 | biostudies-literature